# Draft Industry Summary S02 > Guides preparation of an industry and market analysis memo for a diagnostics acquisition by cross-checking sell-side and independent data, quantifying reimbursement-driven financial impact, flagging customer concentration with imminent contract expiration, and providing a recency-adjusted precedent transaction multiple. - Skill: `finchipaiorg/draft-industry-summary-s02` (Agent Skill) - Install (CLI): `npx skillmds@latest add finchipaiorg/draft-industry-summary-s02` - Raw SKILL.md: https://api.skillmd.com/api/skills/finchipaiorg/draft-industry-summary-s02/raw - Safety review: pending - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Coding & Dev Tools - Author: FinchipAIOrg (https://skillmd.com/u/finchipaiorg) - Updated: 2026-09-22 - Page: https://skillmd.com/skills/finchipaiorg/draft-industry-summary-s02 --- # Skill: Draft Industry Summary Memo for Diagnostics Acquisition ## 1. Subject-matter triage - Treat the assignment as a cross-source diligence memo, not a pure market overview. - Separate core market facts from deal-specific risks, then reconcile sell-side claims against independent research and internal strategy notes. - If the source set includes multiple markets, product lines, geographies, payor regimes, or transaction comps, enumerate them first and analyze each separately rather than blending them into one blended conclusion. - If only one relevant customer, reimbursement event, regulatory regime, or comp set exists, state that explicitly and explain why no broader set is in scope. ## 2. Failure modes the skill is correcting - Repeating sell-side market sizing, share, or growth claims without checking the base year, methodology, or independent confirmation. - Treating an apparent market leader or high-growth segment as verified when the underlying source data are stale, selectively framed, or measured on inconsistent bases. - Ignoring customer concentration when a major relationship is near renewal or expiration during the deal timeline. - Describing reimbursement cuts, regulatory change, or certification delays qualitatively without translating them into financial impact. - Assuming pipeline revenue as if early-stage products were near-commercial or fully de-risked. - Using precedent transactions mechanically when older or atypical deals distort the median. - Missing discrepancies between external materials and internal strategy documents on international revenue or OTC growth. ## 3. Legal frameworks / domain conventions that apply - Customer concentration and renewal risk are material diligence points in healthcare diagnostics; identify the customer, the revenue exposure, the contract timing, and the transaction-window overlap, then explain the revenue and closing implications. - Reimbursement reductions should be translated into revenue and EBITDA impact using the applicable revenue base and any documented offsetting cost changes; do not leave the effect at the narrative level. - Laboratory-developed test regulatory change should be analyzed in light of the governing rule, any legal challenges, and any phased implementation; near-term impact may be overstated if compliance ramps gradually. - EU in vitro diagnostics certification constraints should be assessed against the applicable conformity-assessment regime and the capacity of third-party reviewers; revenue forecasts that depend on new certification should be timing-risk adjusted. - Recency-sensitive precedent transaction analysis should separate older or outlier deals from the relevant current market set and present both the unadjusted and adjusted benchmark where the difference is material. - Pipeline products must be described at their actual development stage; feasibility-stage products are pre-commercial and should not be treated as near-term revenue with certainty. - Any legal or regulatory conclusion must identify the governing authority, rule, or regulation relied on, rather than stating the conclusion in shorthand. ## 4. Analytical scaffolds - Start by mapping the source set into: market data, customer and commercial contracts, reimbursement and regulatory items, pipeline and product development, precedent transactions, and any internal-versus-external inconsistencies. - For market size and growth: - identify the base year used by the sell-side materials; - compare the stated figures to independent research; - note whether differences are methodological, timing-based, or substantive. - For market share: - compare the stated share with independent sources; - state both figures and assess which is more credible and why. - For customer concentration: - identify the largest customer relationships and the share of revenue they represent; - flag any contract expiring during or shortly after the contemplated transaction period; - explain the revenue exposure and any negotiating leverage or retention risk. - For reimbursement changes: - identify each rate adjustment and the affected revenue base; - show the annual revenue effect and the resulting EBITDA effect after any offsets disclosed in the source materials. - For laboratory-developed test change: - identify the governing rule and any litigation or implementation phase; - assess whether the timing makes the near-term impact smaller than the headline suggests. - For EU certification risk: - determine whether current or pipeline products need additional certification; - assess the probability and timing risk associated with constrained review capacity. - For precedent transactions: - identify older or unusual deals that may inflate the median; - present an adjusted benchmark alongside the unadjusted one and explain the valuation implication. - For pipeline products: - state the actual development stage; - align commercialization timing to that stage; - discount revenue expectations where success is still uncertain. - For OTC growth: - test whether recent volume growth appears durable or tied to one-time demand, stocking, or channel effects. - Where the source materials conflict, prefer the more current, more directly supported, and methodologically consistent source, but explain the reconciliation rather than silently choosing one. ## 5. Vertical / structural / temporal relationships - Track how commercial concentration, reimbursement pressure, and regulatory timing interact across the deal timeline. - Distinguish immediate, near-term, and longer-dated impacts so that a risk with delayed effect is not presented as an immediate earnings hit. - When a customer renewal, reimbursement cut, or certification delay overlaps with the expected closing or integration window, state the timing overlap and the practical consequence. - If the source materials contain both external market data and internal planning assumptions, flag any divergence by topic and explain whether the gap is material or cosmetic. - If multiple products or geographies are involved, compare them on the same basis before drawing a portfolio-level conclusion. ## 6. Output structure conventions - Write the deliverable as an industry and market analysis memo with sectioned discussion by topic. - Include a compact market data comparison table showing sell-side figure, independent figure, and a short assessment. - Include a customer concentration section that identifies the relevant customer exposure and any near-term contract timing issue. - Include a regulatory and reimbursement section that translates headline items into financial impact where possible. - Include a precedent transactions section that states both the raw and recency-adjusted valuation benchmark when needed. - Include a short section on pipeline and commercialization risk that ties product stage to revenue realism. - End with a concise recommendations section that turns the diligence findings into action items for the investment committee or deal team, assigning each item to a responsible role and timing it to the deal process. - Keep the memo analytical and source-based; do not pad with generic industry background that does not inform the acquisition decision.